DIAGNOS Announces Signing of Service Agreement with the Colombian Telemedicine Centre
14 July 2020 - 11:49PM
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues using advanced Artificial Intelligence (AI), is pleased to
announce a service agreement with the Colombian Telemedicine Centre
Ltd (“CTMC”).
The CTMC selected DIAGNOS’ AI engine CARA to
start screening Colombia’s population in alliance with the largest
and most well-renowned specialist center in the country. The aim is
to commence the screening project in the following weeks in two
major regions of Colombia. CARA will empower local technicians.
Automated results will be validated by the specialists in order to
schedule and follow up only the patients that need to be
treated.
“The CTMC was founded and launched in 2005
aiming to foster a Telemedicine environment, eHealth service in
order to overcome the difficulties of having access to healthcare.
Today we seize the opportunity hand-to-hand with DIAGNOS to
unburden the heavy costs of blindness caused by diabetes at the
time thousands of patients will have access to a real-time eye
analysis”, said Dr. Jorge Alberto Velez B.,
Director and Founder of the
CTMC.
“We would like to thank the CTMC for choosing
our CARA platform. We believe that CARA is a perfect fit as the
main engine of the telemedicine solution. After a successful eye
screening program with Bayer in 2015, we return to Colombia to
engage our AI service into a practical solution for the local
community. Along with CTMC, we can add value by making our unique
service accessible”, said André Larente,
President of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet and is compatible with all
recognized image formats and brands of fundus cameras and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024